PELL Bio-Med Technology Co (TPE:6949) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
PELL Bio-Med Technology Co had a gross margin of 22.21% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
PELL Bio-Med Technology Co Gross Margin % Related Terms
PELL Bio-Med Technology Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6949 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, PELL Bio-Med Technology Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PELL Bio-Med Technology Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PELL Bio-Med Technology Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where PELL Bio-Med Technology Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
PELL Bio-Med Technology Co (TPE:6949) has a Gross Margin % of 22.21% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on PELL Bio-Med Technology Co and its competitors. According to the industry distribution chart, PELL Bio-Med Technology Co ranks #685 out of 735 companies in the Biotechnology industry, placing it in the top 93.2%.
Is PELL Bio-Med Technology Co's Gross Margin % too high?
PELL Bio-Med Technology Co's current Gross Margin % is 22.21%. The Biotechnology industry median Gross Margin % is 60.90. PELL Bio-Med Technology Co's value of 22.21% is 63.5% below this industry median. Based on the distribution chart, PELL Bio-Med Technology Co ranks #685 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PELL Bio-Med Technology Co has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does PELL Bio-Med Technology Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PELL Bio-Med Technology Co ranks #685 out of 735 companies for Gross Margin %. This places PELL Bio-Med Technology Co in the lower half of its industry. The industry median Gross Margin % is 60.90. PELL Bio-Med Technology Co's value of 22.21% is 63.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PELL Bio-Med Technology Co's current Gross Margin % of 22.21% is 63.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on PELL Bio-Med Technology Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PELL Bio-Med Technology Co's current Gross Margin % is 22.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PELL Bio-Med Technology Co stock overvalued right now?
PELL Bio-Med Technology Co (TPE:6949) has a current Gross Margin % of 22.21%. The current Gross Margin % is 22.21% and 63.5% below the Biotechnology industry median of 60.90. PELL Bio-Med Technology Co's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For PELL Bio-Med Technology Co (TPE:6949), the current Gross Margin % is 22.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PELL Bio-Med Technology Co Ltd is a company engaged in the research and development and application of autologous T Cell Therapy (Adoptive T Cell Therapy), CAR-T (Chimeric Antigen Receptor T cell), and Gene-Modified Adipose-Derived Stem Cell (Gene-Modified Adipose-Derived Stem Cell). The company's segments includes Cell products, Consulting services, and Others.
13GF Score
Get the complete analysis for TPE:6949
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6949 has been successfully added to your 
